Marion Subklewe, MD, from LMU-University Hospital, Munich, Germany, discusses the necessity to monitor T-cell count in patients who will be subject to immunotherapy and to make sure that patients do not receive any prior treatment that would affect their T-cell count (e.g. cytarabine). This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.